Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice

Peptides

Volumn 29, Issue 6, 2008, Pages 1036-1041

  Irwin, Nigel ^a   Hunter, Kerry ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

AM251; CB1 receptor; Food intake; Gastric inhibitory polypeptide (GIP); Glucose homeostasis; High fat feeding

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPID DIET; MONOTHERAPY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

ANIMALS; APPETITE; AREA UNDER CURVE; BLOOD GLUCOSE; BODY WEIGHT; DIETARY FATS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; EATING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INJECTIONS, INTRAPERITONEAL; INSULIN; INSULIN RESISTANCE; MICE; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

MUS; STEATOMYS PRATENSIS;

EID: 43049093733     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.01.006     Document Type: Article

References (34)

1. 1) receptors. Psychopharmacology (Berl) 132 (1997) 104-106
2. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
3. Burington R.S. Handbook of mathematical tables and formulae (1973), McGraw-Hill, New York
4. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., and Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63 (1998) pp. PL131-117
5. Cota D., Genghini S., Pasquali R., and Pagotto U. Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity. J Endocrinol Invest 26 (2003) 1041-1044
6. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
7. Finer N. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabetes Vasc Dis 5 (2005) 121-124
8. Flatt P.R., and Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20 (1981) 573-577
9. Foltin R.W., Fischman M.W., Pedroso J.J., and Pearlson G.D. Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav 28 (1987) 459-464
10. Gault V.A., O'Harte F.P., Harriott P., and Flatt P.R. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290 (2002) 1420-1426
11. Gault V.A., O'Harte F.P., and Flatt P.R. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?. Neuropeptides 37 (2003) 253-263
12. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54 (2005) 2436-2446
13. Gault V.A., McClean P.L., Cassidy R.S., Irwin N., and Flatt P.R. Chemical GIP receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high fat and cafeteria diets. Diabetologia 50 (2007) 1752-1762
14. Getty-Kaushik L., Song D.H., Boylan M.O., Corkey B.E., and Wolfe M.M. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 14 (2006) 1124-1131
15. Hansotia T., Maida A., Flock G., Yamada Y., Tsukiyama K., Seino S., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117 (2007) 143-152
16. 1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 462 (2003) 125-132
17. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002) 161-202
18. Irwin N., Hunter K., and Flatt P.R. Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice. Peptides 28 (2007) 2192-2198
19. 3)GIP, prevents the development of diabetes and related metabolic abnormalities associated with genetically-inherited obesity in ob/ob mice. Diabetologia 50 (2007) 1532-1540
20. Irwin N., Hunter K., Frizzell N., and Flatt P.R. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. Eur J Pharm 1-2 (2008) 226-233
21. Kim S.J., Nian C., and McIntosh C.H. Activation of lipoprotein lipase (LPL) by glucose-dependent insulinotropic polypeptide (GIP) in adipocytes: A role for a protein kinase B (PKB), LKB1 and AMP-activated protein kinase (AMPK) cascade. J Biol Chem 282 (2007) 8557-8567
22. Kirkham T.C., and Williams C.M. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl) 153 (2001) 267-270
23. 1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes 29 (2005) 183-187
24. Mattes R.D., Engelman K., Shaw L.M., and Elsohly M.A. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 49 (1994) 187-195
25. McClean P.L., Irwin N., Cassidy R.S., Holst J.J., Gault V.A., and Flatt P.R. GIP receptor antagonism reverses obesity, insulin resistance and associated metabolic disturbances induced in mice by prolonged consumption of high fat diet. Am J Physiol Endocrinol Metab 293 (2007) E1746-E1755
26. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8 (2002) 738-742
27. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
28. 1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28 (2004) 640-648
29. 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9 (1998) 179-181
30. Stevens J.F. Determination of glucose by an automatic analyser. Clin Chem Acta 32 (1971) 199-201
31. Williams C.M., Rogers P.J., and Kirkham T.C. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 65 (1998) 343-346
32. Woods S.C., West D.B., Stein L.J., McKay L.D., Lotter E.C., Porte S.G., et al. Peptides and the control of meal size. Diabetologia 20 (1991) S305-S313
33. Yamada Y., Miyawaki K., Tsukiyama K., Harada N., Yamada C., and Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 55 (2006) S86-S91
34. Zhou H., Yamada Y., Tsukiyama K., Miyawaki K., Hosokawa M., Nagashima K., et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 335 (2005) 937-942